Atlas Trials

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

Clinical trial NCT00033462 · COMPLETED

Trial details

NCT number
NCT00033462
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Adult Primary Cholangiocellular CarcinomaAdult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerCholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver CancerRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder Cancer
Start date
2002-03-01
Primary completion
2006-11-01
Enrollment
78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.